Immunome (IMNM) reported a 2024 net loss Wednesday of $5 per diluted share, narrowing from the loss of $5.38 a year earlier.
Analysts polled by FactSet expected a loss of $4.38.
Collaboration revenue fell to $9.04 million from $14 million a year earlier.
Analysts surveyed by FactSet expected $9.4 million.
As of Dec. 31, the company had cash, cash equivalents and marketable securities of $217.3 million, excluding gross proceeds of $172.5 million from financing in January, the company said. The current cash runway is expected to extend into 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.